Neural Pathway · T & B Cell Activation

The Two-Signal Rule for T-Cell Activation

Core concept

A naive T cell needs two independent signals before it commits to activation — one alone isn't enough.

Signal	Molecules	Purpose
Signal 1 — specificity	TCR binds MHC:peptide; CD4 (with MHC II) or CD8 (with MHC I) stabilizes the grip; CD3 transduces the signal	Confirms this T cell actually matches the presented antigen
Signal 2 — costimulation	B7 (CD80/CD86) on the APC binds CD28 on the T cell	Confirms real danger is present, not just a stray self-peptide

Adhesion molecules (integrins, Ig-superfamily CAMs) glue the APC and T cell together long enough to form a stable contact — the immune synapse.
B7 expression on APCs is low at baseline and rises sharply during infection/inflammation — this is what keeps resting self-antigen presentation from accidentally activating T cells.

Signal 1 without signal 2 doesn't just fail to activate — it can push the T cell toward anergy (functional unresponsiveness).

T-cell two-signal activation model — YouTube Short

▶ T-cell two-signal activation · @StepWiseUSMLE

Turning the Response Back Off: CTLA-4 and PD-1

Negative regulation + drugs

CTLA-4 appears on activated Th cells and Tregs later in the response.
It out-competes CD28 for the same B7 ligands — same lock, higher-affinity key, opposite outcome (inhibitory instead of activating).
Loss of CTLA-4 removes the brake entirely — in animal models this produces uncontrolled lymphoproliferation; in humans, CTLA-4 dysfunction is linked to autoimmune disease.

Drug	Type	Use
Abatacept	CTLA-4 agonist (fusion protein)	Rheumatoid arthritis
Belatacept	CTLA-4 agonist (fusion protein)	Renal transplant, prevents rejection
Ipilimumab	CTLA-4 antagonist (blocking antibody)	Melanoma and other cancers — releases the brake so T cells attack tumor

Blocking CTLA-4 frees up B7 to bind CD28 instead — that's the whole mechanism behind checkpoint-inhibitor cancer drugs like ipilimumab.

Once activated, CD4+ T cells make IL-2 and upregulate high-affinity IL-2 receptors — an autocrine proliferation loop.
CD8+ T cells make comparatively little IL-2 themselves and lean on IL-2 from helper T cells to expand and differentiate.

Superantigens: Activation Without Real Specificity

Clinical correlate

Certain microbial toxins bridge the outside of a TCR's variable β chain directly to the outside of an MHC class II molecule — completely bypassing the normal peptide groove.
No antigen specificity is required, so this activates every T cell that happens to carry a matching variable β segment — a large, non-specific (polyclonal) chunk of the T-cell pool.

Superantigen bridges TCR-Vβ + MHC II→ Massive polyclonal T-cell activation→ Surge of IFN-γ→ Macrophage activation→ Flood of IL-1, IL-6, TNF-α→ Systemic toxicity

Classic superantigen sources: staphylococcal enterotoxins, toxic shock syndrome toxin-1 (TSST-1), streptococcal pyrogenic exotoxins.

Choosing a Fighting Style: Th1, Th2, Th17, Treg

Fate decision

All arise from the same naive precursor (Th0), which still requires the standard two-signal activation (TCR:MHC II + B7:CD28).
The deciding factor is the surrounding cytokine environment, which itself reflects what kind of pathogen triggered the innate response.

Subset	Driving trigger	Key inducing cytokines	Master transcription factor	Signature output	Main job
Th1	Intracellular pathogens (viruses, intracellular bacteria)	IL-12 (macrophages), IFN-γ (NK cells)	T-bet	IFN-γ	Classical macrophage activation, IgG switching, self-amplifies while suppressing Th2
Th2	Large extracellular parasites (helminths), allergens	IL-4 (produced constitutively at baseline, amplified by mast cells/eosinophils)	GATA-3	IL-4, IL-5, IL-10, IL-13	IgE switching, eosinophil maturation, alternative macrophage activation; suppresses Th1
Th17	Extracellular bacteria and fungi	IL-1, IL-6, IL-23, TGF-β	RORγT	IL-17, IL-22	Neutrophil recruitment, boosts epithelial antimicrobial secretion and barrier integrity
Treg	Arises from Th0 as a regulatory branch	—	FoxP3 (with constitutive CD25)	IL-10, TGF-β	Suppresses Th1 activity; central to preventing autoimmunity

Th1 and Th2 mutually inhibit each other — whichever gets an early cytokine head start tends to dominate the whole response.

Clinical Correlate: Leprosy as a Th1/Th2 Spectrum

Mycobacterium leprae

Tuberculoid pole: strong Th1 response, granuloma formation controls the organism, some nerve/skin damage, slow or absent progression.

Lepromatous pole: Th2-dominant, reciprocal inhibition suppresses the cell-mediated arm, non-protective antibodies form, organism proliferates widely inside macrophages, disseminated and disfiguring disease.

This is a favorite exam illustration of why "more antibody" isn't automatically "better outcome" — the wrong subset dominance can actively worsen an intracellular infection.

Building a Cytotoxic T Lymphocyte

CD8+ pathway

Same two-signal framework as CD4+ cells, but signal 1 comes from MHC class I rather than class II.
CD8+ T cells are comparatively poor IL-2 producers on their own.
They depend heavily on IL-2 supplied by activated helper T cells to proliferate and mature into full cytotoxic effectors.

This dependency is exactly why CD4+ helper loss (e.g., in advanced HIV) cripples effective cytotoxic T-cell responses even when CD8+ cells are still present.

Two Roads to B-Cell Activation: TI vs. TD Antigens

Antigen categories

Naive B cells home to follicles in lymph nodes and spleen; antigen cross-linking surface immunoglobulin is always signal 1.

Feature	Thymus-independent (TI)	Thymus-dependent (TD)
Typical antigen	Repetitive macromolecules — polysaccharides, LPS, lipids	Most protein antigens
T-cell help required	No — direct B-cell stimulation, sometimes acting as a mitogen	Yes — direct B–T conjugate formation required
Antibody produced	Mostly IgM	Full range via isotype switching
Memory generated	Little to none	Robust memory B-cell formation
Location	Spleen marginal zone, mucosal B-1 cells	Follicles/germinal centers of nodes and spleen

TD activation, step by step

Antigen cross-links BCR→ Endocytosed, processed exogenously→ Peptide loaded on MHC II→ B cell upregulates B7→ CD4+ T cell recognizes peptide:MHC II→ B–T conjugate forms→ CD40L (T cell) binds CD40 (B cell) = signal 2→ Directed cytokine release into the synapse→ B-cell proliferation + differentiation

CD40–CD40L is the B-cell equivalent of the B7–CD28 costimulatory handshake on the T-cell side.

Inside the Germinal Center: Sharpening the Response

Affinity maturation + isotype switching

TD-activated B cells split into two waves:
- Early wave — IgM-only plasma cells that exit quickly for an immediate, if lower-affinity, response.
- Later wave — cells that stay in the follicle and build a germinal center, undergoing refinement before becoming effectors.

Affinity maturation

Rapid B-cell proliferation→ Somatic hypermutation of variable-region DNA→ Random affinity changes→ Higher-affinity clones out-compete for antigen→ Clonal selection favors best binders

As isotype switching trades away IgM's high avidity (from its pentameric form), affinity maturation compensates by raising per-site binding strength.

Isotype switching

Same antigen-binding variable region (idiotype) is kept — only the heavy-chain constant region changes, swapping effector function.
Mechanism: DNA between switch regions loops out and is permanently excised, joining the variable region to a new downstream constant gene.
One-directional — once the DNA for an upstream isotype (like IgM) is deleted, that cell's lineage can never revert to making it again.

This is why IgM is always the signature of a first-time exposure — a cell has to be encountering that antigen for the very first time to still have its unswitched IgM machinery intact.

Quick-Fire Exam Pearls

Rapid review

Two signals, always: TCR:MHC (specificity) + B7:CD28 (costimulation).
CTLA-4 beats CD28 for B7 binding — that's the entire logic behind checkpoint-inhibitor cancer drugs.
Superantigens skip the peptide groove entirely — no TCR:MHC complementarity needed.
IL-12 → Th1 (T-bet); IL-4 → Th2 (GATA-3); IL-1/6/23/TGF-β → Th17 (RORγT).
CD25 + FoxP3 = Treg signature; think "brake on Th1."
TI antigens: no T-cell help, IgM only, no memory. TD antigens: T-cell help required, full isotype menu, memory generated.
CD40–CD40L is signal 2 for B cells, the direct analog of B7–CD28 for T cells.
Isotype switching is a one-way DNA deletion — never reversible within a given cell lineage.